CTOs on the Move

SpineGuard

www.spineguard.com

 
Founded in 2009 in France and the USA by Pierre Jerome and Stephane Bette, SpineGuard is an innovative company deploying its proprietary radiation-free real time sensing technology DSG® (Dynamic Surgical Guidance) to secure and streamline the placement of implants in the skeleton. SpineGuard designs, develops and markets medical devices that have been used in over 80,000 surgical procedures worldwide. Sixteen studies published in peer-reviewed scientific journals have demonstrated the multiple benefits DSG® offers to patients, surgeons, surgical staff and hospitals. Building on these solid fundamentals and several strategic partnerships, SpineGuard has expanded its technology platform in a disruptive innovation: the ...
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.spineguard.com
  • 1434 Spruce Street Suite 100
    Boulder, CO USA 80302
  • Phone: 720.726.8085

Executives

Name Title Contact Details

Similar Companies

Becon Medical

Becon Medical is a Tucson, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

LKC Technologies

LKC Technologies is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kinex Medical Company

Kinex Medical Company is a Waukesha, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

EY LABS

EY LABS is a San Mateo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tearlab

TearLab Corporation develops and commercializes lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by quantitatively testing for disease markers in tears at the point-of-care. Headquartered in San Diego, CA, TearLab Corporation`s common shares trade on the NASDAQ Capital Market under the symbol `TEAR` and on the Toronto Stock Exchange under the symbol `TLB`. Dry Eye Disease (DED) is a chronic, progressive disease. Morgan Stanley’s Dry Eye Market Report (2003) estimates that 30 to 60 million Americans suffer from dry eye symptoms. Only 10 million are diagnosed with the disease. Millions more suffer worldwide. The TearLab™ Osmolarity System provides the first quantitative and objective diagnostic technology that allows doctors to effectively manage their dry eye patients. TearLab will allow practitioners to diagnosis DED patients early in the disease process allowing for early intervention. TearLab received the CE Mark for its TearLab Osmolarity System in 2008 and FDA Clearance in 2009. TearLab is currently marketed globally in more than 14 countries including the US.